Ulcerative Colitis Market 2016 Pipeline Review of 108 Companies - Seite 2

Drug Profiles discussed in this research are ABS-11, adalimumab biosimilar, AKP-11, amiselimod hydrochloride, Anatabine, Antisense RNAi Oligonucleotide to Inhibit microRNA-214 for Ulcerative Colitis and Colon Cancer, AVX-470, AW/EPO-002, AW/EPO-003, AW/EPOPD-01, AW/EPOPD-02, AW/EPOPD-06, brilacidin tetrahydrochloride, CCX-507, CKD-506, D-9030, dolcanatide, Drug to Inhibit Calpain-2 for Crohn's Diseases and Ulcerative Colitis, EFFI-7H, EG-10, EG-12, enalaprilat, golimumab biosimilar, GSK-2982772, hyaluronate sodium, IAC VITA, IMO-9200, infliximab biosimilar, INN-108, INV-88, KANAb-071, kPPF-1, KY-1006, lipidated tacrolimus, Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn's Disease, NRG-4, ozanimod hydrochloride, P-Dex, PH-44, PH-46A, PH-5, PNQ-201, Prozumab, PTG-100, ranibizumab biosimilar, RBX-2660, RBX-8225, Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia, Rosburix, SER-287, SER-301, Small Molecule to Agonize S1PR1 for Ulcerative Colitis, Small Molecule to Scavenge Nitric Oxide Radical for Ulcerative Colitis and Inflammation, Small Molecules to Inhibit IL-13 for Ulcerative Colitis, Stem Cell Therapy for Inflammatory Bowel Disease, TAK-114, TD-1473, TOP-1288, TP-10 and VEN-120.

Order a copy of Ulcerative Colitis - Pipeline Review, H1 2016 market research report @ http://www.lifescienceindustryresearch.com/purchase?rname=113853 .

Another newly published market research report titled on Enterocolitis - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Enterocolitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterocolitis and special features on late-stage and discontinued projects. Companies discussed in this research are Angothera GmbH, AvidBiotics Corp., Infant Bacterial Therapeutics AB and Sigma-Tau Pharmaceuticals, Inc. Enterocolitis Pipeline market research report of 43 pages is available at http://www.lifescienceindustryresearch.com/enterocolitis-pipeline-review-h1-2016.html .